GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Deep Medicine Acquisition Corp (NAS:DMAQ) » Definitions » ROE %

Deep Medicine Acquisition (Deep Medicine Acquisition) ROE % : -154.18% (As of Sep. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Deep Medicine Acquisition ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Deep Medicine Acquisition's annualized net income for the quarter that ended in Sep. 2023 was $-1.08 Mil. Deep Medicine Acquisition's average Total Stockholders Equity over the quarter that ended in Sep. 2023 was $0.70 Mil. Therefore, Deep Medicine Acquisition's annualized ROE % for the quarter that ended in Sep. 2023 was -154.18%.

The historical rank and industry rank for Deep Medicine Acquisition's ROE % or its related term are showing as below:

DMAQ' s ROE % Range Over the Past 10 Years
Min: -2.34   Med: -0.65   Max: -0.63
Current: -2.34

During the past 3 years, Deep Medicine Acquisition's highest ROE % was -0.63%. The lowest was -2.34%. And the median was -0.65%.

DMAQ's ROE % is not ranked
in the Diversified Financial Services industry.
Industry Median: 0.54 vs DMAQ: -2.34

Deep Medicine Acquisition ROE % Historical Data

The historical data trend for Deep Medicine Acquisition's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Deep Medicine Acquisition ROE % Chart

Deep Medicine Acquisition Annual Data
Trend Mar21 Mar22 Mar23
ROE %
- -0.67 -0.63

Deep Medicine Acquisition Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.54 3.64 -91.29 -43.24 -154.18

Competitive Comparison of Deep Medicine Acquisition's ROE %

For the Shell Companies subindustry, Deep Medicine Acquisition's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Deep Medicine Acquisition's ROE % Distribution in the Diversified Financial Services Industry

For the Diversified Financial Services industry and Financial Services sector, Deep Medicine Acquisition's ROE % distribution charts can be found below:

* The bar in red indicates where Deep Medicine Acquisition's ROE % falls into.



Deep Medicine Acquisition ROE % Calculation

Deep Medicine Acquisition's annualized ROE % for the fiscal year that ended in Mar. 2023 is calculated as

ROE %=Net Income (A: Mar. 2023 )/( (Total Stockholders Equity (A: Mar. 2022 )+Total Stockholders Equity (A: Mar. 2023 ))/ count )
=-0.4/( (123.989+2.554)/ 2 )
=-0.4/63.2715
=-0.63 %

Deep Medicine Acquisition's annualized ROE % for the quarter that ended in Sep. 2023 is calculated as

ROE %=Net Income (Q: Sep. 2023 )/( (Total Stockholders Equity (Q: Jun. 2023 )+Total Stockholders Equity (Q: Sep. 2023 ))/ count )
=-1.08/( (2.293+-0.892)/ 2 )
=-1.08/0.7005
=-154.18 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Sep. 2023) net income data. ROE % is displayed in the 30-year financial page.


Deep Medicine Acquisition  (NAS:DMAQ) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Sep. 2023 )
=Net Income/Total Stockholders Equity
=-1.08/0.7005
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-1.08 / 0)*(0 / 8.509)*(8.509 / 0.7005)
=Net Margin %*Asset Turnover*Equity Multiplier
=N/A %*0*12.147
=ROA %*Equity Multiplier
=N/A %*12.147
=-154.18 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Sep. 2023 )
=Net Income/Total Stockholders Equity
=-1.08/0.7005
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-1.08 / -1.08) * (-1.08 / -1.444) * (-1.444 / 0) * (0 / 8.509) * (8.509 / 0.7005)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1 * 0.7479 * N/A % * 0 * 12.147
=-154.18 %

Note: The net income data used here is four times the quarterly (Sep. 2023) net income data. The Revenue data used here is four times the quarterly (Sep. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Deep Medicine Acquisition ROE % Related Terms

Thank you for viewing the detailed overview of Deep Medicine Acquisition's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Deep Medicine Acquisition (Deep Medicine Acquisition) Business Description

Traded in Other Exchanges
N/A
Address
595 Madison Avenue, 12th Floor, New York, NY, USA, 10017
Website
Deep Medicine Acquisition Corp is a blank check company.
Executives
John Chiang director 3538 TORRANCE BLVD., UNIT 177, TORRANCE CA 90503
Bryant Fong director 2170 VALLEJO STREET #101, SAN FRANCISCO CA 94123
Humphrey P Polanen director, officer: Chief Executive Officer C/O HERITAGE COMMERCE CORP, 150 ALMADEN BLVD, SAN JOSE CA 95113
Weixuan Luo officer: Chief Financial Officer 40 WALL STREET, 29TH FLOOR, NEW YORK NY 10005
Marc Hamer director 7951 S.W. 6TH STREET, SUITE 216, PLANTATION FL 33324
Bright Vision Sponsor Llc 10 percent owner 7951 S.W. 6TH STREET, SUITE 216, PLANTATION FL 33324
Ronald M. Razmi director 7951 S.W. 6TH STREET, SUITE 216, PLANTATION FL 33324
Hongliang Ren director 7951 S.W. 6TH STREET, SUITE 216, PLANTATION FL 33324
Wanlei Miao director 595 MADISON AVENUE, 12TH FLOOR, NEW YORK NY 10017
Tina Spires director 595 MADISON AVENUE, 12TH FLOOR, NEW YORK NY 10017

Deep Medicine Acquisition (Deep Medicine Acquisition) Headlines

From GuruFocus

Deep Medicine Acquisition Corp. Announces Appointment of a New Director

By Value_Insider Value_Insider 10-24-2022

Deep Medicine Acquisition Corp. Announces Appointment of a New Director

By GlobeNewswire GlobeNewswire 10-24-2022